Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709082 · ClinicalTrials.gov registry record · Phase 1
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
A Phase 1 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03709082 is a Phase 1 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT03709082, a Phase 1 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will determine the recommend dose of palbociclib in combination with letrozole and another medication, Ado-trastuzumab emtansine (T-DM1). Additionally, researchers will determine how well this recommended dose will improve outcomes in this type of advanced breast cancer. The study will include a safety lead-in with escalating dosing of palbociclib to determine the recommended phase II dose (RP2D) of palbociclib in this combination and an expanded phase II of palbociclib at the RP2D in combination with letrozole and Ado- trastuzumab Emtansine (T-DM1). The starting dose of palbociclib will be 75 milligrams (mg) by mouth (PO) daily for each 21 day cycle. If 0 of 3 patients at the 75mg dose level experience a dose limiting toxicity (DLT), the next 3 patients will be enrolled at the next higher dosing cohort of 100mg PO daily for each 21 day cycle. If 0 of 3 patients at the 100mg dose level experience a DLT, the next 3 patients will be enrolled at the next higher dosing cohort of 125mg PO daily for each 21 day cycle. If 0 of 3 patients at the 125mg dose level experience a DLT, 125mg PO daily of palbociclib will be the phase II recommended dose used in the phase II expanded cohort. Patients receiving the phase II recommended dose in phase I will be enrolled in phase II of the study. During safety lead-in and expanded phase II, Letrozole 2.5mg PO will be administered daily for each 21 day cycle and T-DM1 3.6 milligrams per kilograms intravenously (IV) will be administered on Day 1 of each 21 day cycle.
Interventions
- DRUG T-DM1
- DRUG Letrozole 2.5mg
- DRUG Palbociclib 125mg
- DRUG Palbociclib 75mg
- DRUG Palbociclib 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2021-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03709082
The ClinicalTrials.gov registry entry for NCT03709082 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which T-DM1 is the first listed.
NCT03709082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03709082 about?
NCT03709082 is a clinical study titled "Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer". This study will determine the recommend dose of palbociclib in combination with letrozole and another medication, Ado-trastuzumab emtansine (T-DM1). Additionally, researchers will determine how well this recommended dose will improve outcomes in this type of advanced breast cancer. The study will i...
What is the current status of trial NCT03709082?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-10-15. Estimated completion is 2021-02-03.
What interventions are being tested in trial NCT03709082?
The interventions under investigation include: T-DM1 (DRUG), Letrozole 2.5mg (DRUG), Palbociclib 125mg (DRUG), Palbociclib 75mg (DRUG), Palbociclib 100mg (DRUG).
Who is sponsoring clinical trial NCT03709082?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.